ライフサイエンスコーパス: stem cell mobilization

1 ce with AMD3100 (plerixafor) and its role in stem cell mobilization.

2 on of HSCs into the hepatic parenchyma after stem cell mobilization.

3 inical trials evaluating novel approaches to stem cell mobilization.

4 f relapse, toxicity, mechanism of action, or stem cell mobilization.

5 Fifty patients were enrolled and underwent stem cell mobilization.

6 00-mediated and G-CSF-mediated hematopoietic stem cell mobilization.

7 eutrophil chemoattraction, angiogenesis, and stem cell mobilization.

8 100), a clinical candidate for hematopoietic stem cell mobilization.

9 f PPM1H as a potential inhibition target for stem cell mobilization.

10 gnaling networks that underlie hematopoietic stem cell mobilization.

11 for HIV infection and plerixafor (CXCR4) for stem-cell mobilization.

12 Rituximab was administered during stem-cell mobilization (1 day before chemotherapy at 375

13 dary end points were: overall response rate, stem-cell mobilization activity, and toxicity.

14 c malignancies, and problems associated with stem cell mobilization after lenalidomide treatment.

15 diabetes-associated defect of hematopoietic stem cell mobilization after stimulation with granulocyt

16 Plerixafor, a hematopoietic stem cell mobilization agent, increases the peripheral b

17 ICE chemotherapy every 21 days, followed by stem cell mobilization and collection, and then 1 cycle

18 rtaken to evaluate the effect of hemopoietic stem cell mobilization and harvesting on HIV-1 replicati

19 ory process overall as well as hematopoietic stem cell mobilization and homing.

20 ng haematopoietic stem cells, haematopoietic stem cell mobilization and lineage determination and B c

21 own of PHD and FIH synergistically increases stem cell mobilization and myocardial angiogenesis, lead

22 viously unknown signaling pathway regulating stem cell mobilization and provide a new pharmacological

23 F nanodiscs had greater activity in inducing stem cell mobilization and recruitment to the site of in

24 he care of patients with diabetes undergoing stem cell mobilization and transplantation and for the v

25 in murine and rhesus monkey peripheral blood stem cell mobilization and transplantation models.

26 cell levels could lead to better methods for stem cell mobilization and transplantation.

27 ypothesize that neuropathy of the BM affects stem cell mobilization and vascular recovery after ische

28 The impact of VDD on stem-cell mobilization and collection also was evaluated

29 As stem-cell mobilization and in vitro culture techniques h

30 progression-free survival, overall survival, stem cell mobilization, and neutrophil and platelet engr

31 emphases on patient selection, approaches to stem cell mobilization, and peri-SCT management.

32 tors and small molecule CXCR4 antagonist for stem- cell mobilization, and in vivo experimental transp

33 ed that the adverse effects of pharmacologic stem cell mobilization are primarily mediated by the con

34 All patients underwent stem cell mobilization before 1:1 randomization to immun

35 p better define the complicated mechanism of stem cell mobilization by G-CSF and point to a wide role

36 visual impairment was reported one day after stem cell mobilization by granulocyte-colony stimulating

37 We confirmed that Treg depletion during stem cell mobilization can mitigate constraints on tumor

38 or a range of clinical conditions, including stem cell mobilization, cancer prognosis and treatment,

39 Augmented stem cell mobilization could also be demonstrated in mic

40 s for venous thromboembolism prophylaxis and stem cell mobilization failure associated with lenalidom

41 Is peripheral stem cell mobilization followed by autologous stem cell

42 o, to receive two additional RVD cycles plus stem-cell mobilization, followed by either five addition

43 d the development of therapies to facilitate stem cell mobilization for clinical purposes.

44 drug,Me6TREN, may have broad applications in stem-cell mobilization for cancer and in regenerative me

45 he US Food and Drug Administration (FDA) for stem cell mobilization in cancer and administered for th

46 AMD3100 was recently FDA-approved for stem cell mobilization in combination with granulocyte-c

47 sion, autonomic neuropathy in the BM impairs stem cell mobilization in diabetes with dysregulation of

48 However, the safety and feasibility of stem cell mobilization in individuals with sickle cell t

49 Optimal methods of stem cell mobilization in multiple myeloma are undefined

50 develop renal insufficiency while undergoing stem cell mobilization in preparation for an autologous

51 proliferation and facilitates hematopoietic stem cell mobilization in vivo, while the stromal-derive

52 ors and induces hematopoietic progenitor and stem cell mobilization in vivo.

53 The STEM-AMI OUTCOME CMR (Stem Cells Mobilization in Acute Myocardial Infarction O

54 of 2 platelet transfusions was required for stem cell mobilization, intravenous catheter insertion,

55 o ICE chemotherapy did not negatively affect stem cell mobilization or collection or engraftment, sim

56 single injection of both agents resulted in stem cell mobilization peaking within 15 min that was eq

57 uding one who required intubation during his stem cell mobilization period.

58 Pretransplantation R did not affect stem-cell mobilization, post-transplantation early compl

59 Here, we demonstrate that endogenous stem cell mobilization produced by AMD3100 and low-dose

60 onstrate in mice that endogenous bone marrow stem cell mobilization, produced by a pharmacologic comb

61 cing its myeloprotective or peripheral blood stem cell mobilization properties, which can be used to

62 use of granulocytosis-inducing hematopoietic stem cell mobilization protocols for the prevention or t

63 In conclusion, plerixafor results in rapid stem cell mobilization regardless of route of administra

64 We developed a rapid stem cell mobilization regimen utilizing a unique CXCR2

65 ing T cells are efficiently mobilized during stem cell mobilization (SCM) and hypothesized that mobil

66 eptors, 5-HT(2B), is involved in bone marrow stem cell mobilization that participates in the developm

67 poraneous with filgrastim administration for stem cell mobilization, the patient's slowly progressive

68 f CXCR4 antagonists is an efficient means of stem cell mobilization, this fails to evoke the immunomo

69 f IGF-1 transgene expression induced massive stem cell mobilization via SDF-1alpha signaling and culm

70 Stem cell mobilization was attempted in 88 patients and

71 Toxicity was largely hematologic, and stem cell mobilization was successful in 43 of 45 patien

72 cause anti-CD49d also supports hematopoietic stem cell mobilization, we sought to determine the thera

73 patients who had been primed with VP-16 for stem cell mobilization were at a 12.3-fold increased ris

74 time of ASCT, disease status, and method of stem-cell mobilization, were then analyzed with respect

75 portant therapeutic target for hematopoietic stem cell mobilization, which enhances the success of au

76 In contrast, stem cell mobilization with the CXCR4 antagonist AMD3100